OverviewSuggest Edit

Adamas Pharmaceuticals discovers and develops therapies to improve the daily lives of people affected by chronic neurologic disorders. The Company pioneered a platform to develop medicines for chronic neurologic disorders, which is built upon its understanding of time-dependent biologic processes responsible for specific disease activities and drug response.

Adamas Pharmaceuticals' lead product candidate, ADS-5102, is a high-dose amantadine therapy in development for the treatment of levodopa-induced dyskinesia in people with Parkinson’s disease. It is also investigating ADS-4101, modified-release lacosamide capsules, for the treatment of partial-onset seizures in patients with epilepsy.

Additionally, Adamas' licensed assets for the treatment of moderate to severe Alzheimer’s disease, Namenda XR® extended-release capsules, and Namzaric® capsules, are currently marketed by Allergan.

TypePublic
Founded2002
HQEmeryville, CA, US
Websiteadamaspharma.com
Employee Ratings3.7
Overall CultureC+

Latest Updates

Employees (est.) (Dec 2019)136(+2%)
Job Openings8
Revenue (FY, 2020)$74.5 M(+37%)
Share Price (Sept 2021)$4.6
Cybersecurity ratingBMore

Key People/Management at Adamas Pharmaceuticals

Neil F. McFarlane

Neil F. McFarlane

Chief Executive Officer
Alf Merriweather

Alf Merriweather

CFO
Christopher B. Prentiss

Christopher B. Prentiss

Chief Financial Officer
Rajiv Patni

Rajiv Patni

Chief Medical Officer / R&D Head
Vijay Shreedhar

Vijay Shreedhar

Chief Commercial Officer
David L. Mahoney

David L. Mahoney

Chairman
Show more

Adamas Pharmaceuticals Office Locations

Adamas Pharmaceuticals has an office in Emeryville
Emeryville, CA, US (HQ)
1900 Powell St #750
Show all (1)

Adamas Pharmaceuticals Financials and Metrics

Adamas Pharmaceuticals Revenue

Adamas Pharmaceuticals's revenue was reported to be $74.46 m in FY, 2020
USD

Revenue (Q1, 2021)

19.3m

Gross profit (Q1, 2021)

18.9m

Gross profit margin (Q1, 2021), %

98%

Net income (Q1, 2021)

(12.6m)

EBIT (Q1, 2021)

(9.5m)

Market capitalization (14-Sept-2021)

206.6m

Closing stock price (14-Sept-2021)

4.6

Cash (31-Mar-2021)

124.8m

EV

211.5m
Adamas Pharmaceuticals's current market capitalization is $206.6 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

55.8m1.9m572.0k571.0k34.0m54.6m74.5m

Revenue growth, %

(97%)(70%)

Cost of goods sold

17.0k633.0k2.5m2.0m

Gross profit

554.0k33.4m52.2m72.4m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

176.0k25.2m215.0k226.0k398.0k768.0k175.0k222.0k138.0k2.0k1.0k2.6m7.6m10.6m13.9m14.5m18.0m19.0m19.3m

Cost of goods sold

25.0k73.0k100.0k413.0k685.0k572.0k385.0k

Gross profit

2.5m7.5m10.5m13.9m18.9m

Gross profit Margin, %

99%99%99%96%98%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

61.4m33.1m23.7m91.3m56.6m65.8m71.7m

Accounts Receivable

524.0k1.3m794.0k367.0k5.5m5.8m8.0m

Prepaid Expenses

3.7m6.9m6.7m13.0m

Inventories

645.0k5.1m2.5m1.7m5.1m5.3m7.3m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

10.2m(51.8m)(60.1m)(89.5m)(131.0m)(105.2m)(57.4m)

Depreciation and Amortization

155.0k435.0k808.0k1.2m851.0k

Inventories

(97.8m)(153.7m)2.1m(1.6m)(3.3m)(970.0k)(2.2m)

Accounts Payable

1.5m(788.0k)502.0k333.0k2.8m398.0k(5.0m)
USDQ1, 2014

Financial Leverage

1.6 x
Show all financial metrics

Adamas Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Adamas Pharmaceuticals Online and Social Media Presence

Embed Graph

Adamas Pharmaceuticals Company Culture

  • Overall Culture

    C+

    76/100

  • CEO Rating

    D

    60/100

  • Compensation

    D-

    50/100

Learn more on Comparably

Adamas Pharmaceuticals News and Updates

Adamas Pharmaceuticals Appoints Neil McFarlane as Chief Executive Officer

- Gregory Went, Ph.D., Founder, transitions to a strategic advisory role

Adamas Pharmaceuticals Welcomes Vijay Shreedhar as Chief Commercial Officer

EMERYVILLE, Calif., May 30, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that Vijay Shreedhar, PhD, has joined the Company as its Chief…

ADAMAS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc.'s January 24, 2018 Secondary Public Offering To Contact The Firm

NEW YORK, May 24, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company")(NASDAQ:ADMS). If you purchased Adamas stock pursuant to the Company's January 24, 2018...

Adamas Pharmaceuticals Blogs

Adamas to Present at Upcoming BofA Conference

Adamas to Present at Upcoming BofA Conference Content Import Thu, 04/29/2021 - 16:05 Adamas to Present at Upcoming BofA Conference April 29, 2021 at 4:04 PM EDT This release is a backfill from a News Wire General EMERYVILLE, Calif…

Adamas Launches “Picture More Time” Campaign to Raise Awareness and Understanding of the Impact of OFF Time and Dyskinesia for People With Parkinson’s Disease and Care Partners

Adamas Launches “Picture More Time” Campaign to Raise Awareness and Understanding of the Impact of OFF Time and Dyskinesia for People With Parkinson’s Disease and Care Partners Content Import Tue, 04/27/2021 - 09:16 Adamas Launches “Picture More Time” Campaign to Raise Awareness and Unders…

Adamas to Announce First Quarter Financial Results and Host Conference Call on May 10, 2021

EMERYVILLE, Calif. --(BUSINESS WIRE)--Apr. 26, 2021-- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report first quarter 2021 financial results on Monday, May 10 , after market close. Subsequently, Adamas’ management team will host a conference call and webcast

Survey data detailing impact of OFF time and dyskinesia in people affected by Parkinson’s disease presented at American Academy of Neurology (AAN) Annual Meeting

Survey data detailing impact of OFF time and dyskinesia in people affected by Parkinson’s disease presented at American Academy of Neurology (AAN) Annual Meeting Content Import Mon, 04/19/2021 - 09:16 Survey data detailing impact of OFF time and dyskinesia in people affected by Parkinson’s…

Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting

EMERYVILLE, Calif. --(BUSINESS WIRE)--Apr. 15, 2021-- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced two posters will be presented at the American

Adamas to Present at Upcoming Needham Conference

EMERYVILLE, Calif. --(BUSINESS WIRE)--Apr. 7, 2021-- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F.
Show more

Adamas Pharmaceuticals Frequently Asked Questions

  • When was Adamas Pharmaceuticals founded?

    Adamas Pharmaceuticals was founded in 2002.

  • Who are Adamas Pharmaceuticals key executives?

    Adamas Pharmaceuticals's key executives are Neil F. McFarlane, Alf Merriweather and Christopher B. Prentiss.

  • How many employees does Adamas Pharmaceuticals have?

    Adamas Pharmaceuticals has 136 employees.

  • What is Adamas Pharmaceuticals revenue?

    Latest Adamas Pharmaceuticals annual revenue is $74.5 m.

  • What is Adamas Pharmaceuticals revenue per employee?

    Latest Adamas Pharmaceuticals revenue per employee is $547.5 k.

  • Who are Adamas Pharmaceuticals competitors?

    Competitors of Adamas Pharmaceuticals include Macleods Pharmaceuticals, Sandoz and Alkem Laboratories.

  • Where is Adamas Pharmaceuticals headquarters?

    Adamas Pharmaceuticals headquarters is located at 1900 Powell St #750, Emeryville.

  • Where are Adamas Pharmaceuticals offices?

    Adamas Pharmaceuticals has an office in Emeryville.

  • How many offices does Adamas Pharmaceuticals have?

    Adamas Pharmaceuticals has 1 office.